Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
October 28, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
October 27, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to...
October 25, 2025 11:01 ET | Source: Sobi, Inc.

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions

NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS...
October 24, 2025 08:59 ET | Source: Research and Markets

United States Immunology KOLs Fair-Market Value Compensation Rates Report 2025: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)

Dublin, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The "United States Fair-Market Value Compensation Rates for Immunology KOLs" report has been added to ResearchAndMarkets.com's offering. This report...
September 30, 2025 08:00 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager...
September 29, 2025 08:56 ET | Source: Research and Markets

Allergy Treatment Global Forecast Report 2025: Market to Grow by Over $20 Billion by 2033, Driven by by Accelerated Illness Prevalence, Climate-driven Allergy Amplification, and Innovative Biologics

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Allergy Treatment Global Market Report by Type, Treatment, Dosage Form, Distribution Channel, Countries and Company Analysis, 2025-2033" report has...
September 29, 2025 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today...
September 25, 2025 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today...
September 23, 2025 10:07 ET | Source: Trethera Corporation

Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease

TRE-515, the only dCK inhibitor in development, secures $1.8M NIH grant after outperforming market-leader Stelara in Crohn’s studies.